» Articles » PMID: 34535684

Synthetic Essentiality Between PTEN and Core Dependency Factor PAX7 Dictates Rhabdomyosarcoma Identity

Abstract

PTEN promoter hypermethylation is nearly universal and PTEN copy number loss occurs in ~25% of fusion-negative rhabdomyosarcoma (FN-RMS). Here we show Pten deletion in a mouse model of FN-RMS results in less differentiated tumors more closely resembling human embryonal RMS. PTEN loss activated the PI3K pathway but did not increase mTOR activity. In wild-type tumors, PTEN was expressed in the nucleus suggesting loss of nuclear PTEN functions could account for these phenotypes. Pten deleted tumors had increased expression of transcription factors important in neural and skeletal muscle development including Dbx1 and Pax7. Pax7 deletion completely rescued the effects of Pten loss. Strikingly, these Pten;Pax7 deleted tumors were no longer FN-RMS but displayed smooth muscle differentiation similar to leiomyosarcoma. These data highlight how Pten loss in FN-RMS is connected to a PAX7 lineage-specific transcriptional output that creates a dependency or synthetic essentiality on the transcription factor PAX7 to maintain tumor identity.

Citing Articles

Myogenesis gone awry: the role of developmental pathways in rhabdomyosarcoma.

Gustafson A, Durbin A, Artinger K, Ford H Front Cell Dev Biol. 2025; 12:1521523.

PMID: 39902277 PMC: 11788348. DOI: 10.3389/fcell.2024.1521523.


A comprehensive analysis of minimally differentially methylated regions common to pediatric and adult solid tumors.

Buckley D, Tew B, Gooden C, Salhia B NPJ Precis Oncol. 2024; 8(1):125.

PMID: 38824198 PMC: 11144230. DOI: 10.1038/s41698-024-00590-1.


miR-497 Target Gene Regulatory Network in Angiosarcoma.

Benton A, Moriarty N, Terwilliger E, Liu B, Murphy A, Maluvac H Mol Cancer Res. 2024; 22(9):879-890.

PMID: 38771248 PMC: 11374500. DOI: 10.1158/1541-7786.MCR-23-1075.


Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside.

Martynov I, Dhaka L, Wilke B, Hoyer P, Vahdad M, Seitz G Front Oncol. 2024; 14:1333129.

PMID: 38371622 PMC: 10869630. DOI: 10.3389/fonc.2024.1333129.


A SNAI2/CTCF Interaction is Required for Expression in Rhabdomyosarcoma.

Sreenivas P, Wang L, Wang M, Challa A, Modi P, Hensch N Mol Cell Biol. 2023; 43(11):547-565.

PMID: 37882064 PMC: 10761179. DOI: 10.1080/10985549.2023.2256640.


References
1.
Kashi V, Hatley M, Galindo R . Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. Nat Rev Cancer. 2015; 15(7):426-39. PMC: 4599785. DOI: 10.1038/nrc3961. View

2.
Skapek S, Ferrari A, Gupta A, Lupo P, Butler E, Shipley J . Rhabdomyosarcoma. Nat Rev Dis Primers. 2019; 5(1):1. PMC: 7456566. DOI: 10.1038/s41572-018-0051-2. View

3.
Chen X, Stewart E, Shelat A, Qu C, Bahrami A, Hatley M . Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013; 24(6):710-24. PMC: 3904731. DOI: 10.1016/j.ccr.2013.11.002. View

4.
Paulson V, Chandler G, Rakheja D, Galindo R, Wilson K, Amatruda J . High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011; 50(6):397-408. DOI: 10.1002/gcc.20864. View

5.
Shern J, Chen L, Chmielecki J, Wei J, Patidar R, Rosenberg M . Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014; 4(2):216-31. PMC: 4462130. DOI: 10.1158/2159-8290.CD-13-0639. View